429.1CD40L-Target Nanoparticles Co-Delivering Sirolimus and CD28 siRNA for the Suppression of Allogeneic Liver Transplantation Rejection
Xiandong Zeng (CN)
Immunosuppression in liver and kidney transplantation
Presentations
Oral Presentation
429.2Imlifidase in highly sensitized kidney transplant recipients with a positive crossmatch against a deceased donor - Results of the French ISKIA Registry
Lionel Couzi (FR)
429.3Encore presentation: The ConfIdeS study: Imlifidase desensitization results in timelier transplant with superior 1-year eGFR among highly sensitized patients compared to control
Robert A. Montgomery (US)
Mini-Oral Presentation
429.4Induction immunosuppression strategy and long-term graft and patient survival in contemporary adult liver transplantation: A United States allocation-era reassessment
Isabella Faria (US)
429.6VISTA positive macrophages define an immature tertiary lymphoid niche in renal allograft tolerance
Rui Shi (CN)
429.7Tacrolimus Exposure Variability and Viral Infection Risk after Kidney Transplantation: A Stratified Analysis Using TTR and CV
Geunbin Park (KR)